Premium
Imaging of dopamine receptors with [ 123 I]iodobenzamide single‐photon emission–computed tomography in neuroleptic malignant syndrome
Author(s) -
Jauss M.,
Krack P.,
Franz M.,
Klett R.,
Bauer R.,
Gallhofer B.,
Dorndorf W.
Publication year - 1996
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870110621
Subject(s) - medicine , neuroleptic malignant syndrome , amantadine , dopamine receptor , single photon emission computed tomography , dantrolene , nuclear medicine , dopamine receptor d2 , positron emission tomography , dopamine , pharmacology , calcium
With the tracer [ 123 I] iodobenzamide;([ 123 I]‐IBZM), it is possible to image dopamine receptor occupancy with singlephoton emission‐computed tomography (SPECT). We report follow‐up examinations with IBZM‐SPECT in neuroleptic malignant syndrome (NMS) to display D 2 ‐receptor availability in the acute phase and during the course of remission. A 27‐year‐old man was admitted with severe akinesia, rigor, tachycardia, fever, and elevated creatine phosphokinase level (CK) after neuroleptic medication. NMS was diagnosed, was started with dantrolene, amantadine, and dopamine agonists. IBZM‐SPECT examination was performed on days 6, 34, 90, 107, 131, and 201. In the acute state of NMS, there was no binding of IBZM to D 2 ‐receptors. SPECT reached almost normal values on day 131, but clinical examination still showed a mild parkinsonian syndrome. With SPECT, the D 2 ‐receptor occupancy in NMS could be successfully shown in correlation with extrapyramidal signs. IBZM‐SPECT may therefore serve to monitor D 2 ‐receptor occupancy in patients at risk for NMS.